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Abstract
Background: The aim of this study is to investigate the relationship between16-slice spiral CT
perfusion imaging and tumor angiogenesis and VEGF (vascular endothelial growth factor)
expression in patients with benign and malignant pulmonary nodules, and differential diagnosis
between benign and malignant pulmonary nodules.
Methods: Sixty-four patients with benign and malignant pulmonary nodules underwent 16-slice
spiral CT perfusion imaging. The CT perfusion imaging was analyzed for TDC (time density curve),
perfusion parametric maps, and the respective perfusion parameters. Immunohistochemical
findings of MVD (microvessel density) measurement and VEGF expression was evaluated.
Results: The shape of the TDC of peripheral lung cancer was similar to those of inflammatory
nodule. PH (peak height), PHpm/PHa (peak height ratio of pulmonary nodule to aorta), BF (blood
flow), BV (blood volume) value of peripheral lung cancer and inflammatory nodule were not
statistically significant (all P > 0.05). Both showed significantly higher PH, PHpm/PHa, BF, BV value
than those of benign nodule (all P < 0.05). Peripheral lung cancer showed significantly higher PS
(permeability surface) value than that of inflammatory nodule and benign nodule (all P < 0.05). BV,
BF, PS, MTT, PH, PHpm/PHa, and MVD among three groups of peripheral lung cancers were not
significantly (all P > 0.05). In the case of adenocarcinoma, BV, BF, PS, PHpm/PHa, and MVD between
poorly and well differentiation and between poorly and moderately differentiation were statistically
significant (all P < 0.05). The peripheral lung cancers with VEGF positive expression showed
significantly higher PH, PHpm/PHa, BF, BV, PS, and MVD value than those of the peripheral lung
cancer with VEGF negative expression, and than those of benign nodule with VEGF positive
expression (all P < 0.05). When investigating VEGF negative expression, it is found that PH, PHpm/
PHa, and MVD of inflammatory nodule were significantly higher than those of peripheral lung
cancer, PS of inflammatory nodule were significantly lower than that of peripheral lung cancer (all
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P < 0.05). PH, PHpm/PHa, BF, and BV of benign nodule were significantly lower than those of
inflammatory nodule (all P < 0.05), rather than PS and MTT (mean transit time) (all P > 0.05). PH,
PHpm/PHa, BV, and PS of benign nodule were significantly lower than those of peripheral lung
cancer (all P < 0.05). In the case of VEGF positive expression, MVD was positively correlated with
PH, PHpm/PHa, BF, BV, and PS of peripheral lung cancer and PS of benign nodule (all P < 0.05).
Conclusion: Multi-slice spiral CT perfusion imaging closely correlated with tumor angiogenesis
and reflected MVD measurement and VEGF expression. It provided not only a non-invasive method
of quantitative assessment for blood flow patterns of peripheral pulmonary nodules but also an
applicable diagnostic method for peripheral pulmonary nodules.
Background
Pulmonary nodule is a kind of common disease found in
the lung. Sometimes it is difficult to directly identify
between malignancy and benignancy of peripheral pul-
monary nodule by using morphology features because of
changes in the blood vessel volume, perfusion and capil-
lary permeability in new tumor vessels which may result
in the changes of blood patterns [1-3]. The method of per-
fusion imaging is effective to detect the differentiation of
blood supply between benign and malignant pulmonary
nodules in quantity and quality [4-8].
The purpose of this study was to quantitatively evaluate
16-slice spiral CT perfusion imaging to describe the blood
patterns of benign and malignant pulmonary nodules and
to investigate the relationship between CT perfusion
imaging and tumor angiogenesis and vascular endothelial
growth factor (VEGF) expression in patients with benign
and malignant pulmonary nodules, and the differential
diagnosis between benign and malignant pulmonary
nodules by using perfusion imaging of 16-slice spiral CT.
Methods
1. Patients
From January 2005 to December 2006, 69 patients with
peripheral pulmonary nodule were studied with informed
consent. All the tumors were conformed by surgery. The
patients underwent 16-slice spiral CT perfusion scanning
in less than a week before surgery. No patients received
any therapy (such as chemotherapy) before surgery. Five
of 69 patients who could not hold their breath, led to
errors in perfusion values and artifacts on parametric
maps, and so were excluded. The other 64 patients (39
men and 25 women; age range, 26–75 years; mean age ±
SD, 51.27 ± 13.83 years; approximately spherical; long-
axis diameters range, 1.6–4.2 cm, mean diameters, 2.8
cm) were included.
The 64 patients included 39 cases of peripheral lung can-
cer (24 adenocarcinoma, 11 squamous cell carcinoma, 2
large cell carcinoma, and 2 small cell carcinoma, long-axis
diameters range, 1.7–4.2 cm, mean diameters, 2.7 cm), 13
cases of inflammatory nodules (8 active inflammatory
granuloma and 5 pneumonia apostematosa, long-axis
diameters range, 2.1–3.9 cm, mean diameters, 3.2 cm), 12
cases of benign nodules (9 tuberculoma and 3 hamar-
toma, long-axis diameters range, 1.6–3.0 cm, mean diam-
eters, 2.5 cm). In the 39 cases of peripheral lung cancer, 24
adenocarcinoma (well, moderately, poorly differentiation
are 9, 10, 5 cases respectively), 11 squamous cell carci-
noma (well, moderately, and poorly differentiation are 6,
4, 1 cases respectively), 11 large and small cell carcinoma
(well, moderately, poorly differentiation are 6, 4, 1 cases
respectively) (Table 1).
The experiments were performed with the approval of the
human subjects ethics committee of the First Affiliated
Hospital, Medical College of Shantou University.
2. Computed tomography scanning
Computed tomography perfusion imaging were per-
formed by using a commercially available 16-slice spiral
CT scanner (Lightspeed, GE, USA). The patients were
instructed in breath-holding and in holding their breath
at full suspended inspiration during quiet breathing so as
to facilitate to repeat imaging of the same tissue volume.
The CT scan involved two steps. Firstly, a conventional CT
scan was performed to find the tumor and determine the
section of perfusion scan. The scan ranged from the tho-
racic inlet to the pulmonary base, with 1.25-mm section
thickness, 1.375 pitch, 10-mm reconstruction thickness,
120-kV tube voltage, 220-mA tube current. Secondly, CT
perfusion scan was performed after the tumor was found.
Four adjacent sections containing the largest nodular
diameter were selected as the target cross sections. Noni-
onic contrast medium ultravist 300 (300 mgI/ml)was
Table 1: Differentiation of peripheral lung cancer
Differentiation of lung tumors Cases Well Moderately Poorly
Adenocarcinoma 24 9 10 5
Squamous cell carcinoma 11 6 4 1
Large and small cell carcinoma 4 3 0 1BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
Page 3 of 17
(page number not for citation purposes)
injected via a superficial antebrachial vein with pressure
syringe at a flow rate of 4 ml/s and a total volume of 50
ml. Perfusion scan was in a cine pattern, with 0.5 s/coil, 5-
mm section thickness × 4, 0-mm interval, no inclination
of scan frame, tube voltage of 120 kV, tube current of 60
mA, exposition time of 40 s, data acquisition time of 40 s,
delay time of 2 s (perfusion scan started after injection of
contrast medium for 2 s).
3. Analysis of CT perfusion images
The 316 images (79 images per section, 4 sections) with 5-
mm reconstruction thickness generated by CT perfusion
were transmitted to AW4.1 workstation via a local area
network. All the data were calculated quantitatively
according to the calculation approach of the deconvolu-
tion model with the CT body perfusion software of GE
perfusion3 and produced perfusion parametric maps
(assigned type). The analysis package offered a motion
correction for in-plane movement. The four sections of
data were respectively analyzed. Air and bone pixels are
excluded from calculations by CT value (Hounsfield Unit,
HU) thresholds, typically -120 to 240 HU.
Firstly, descending aorta (or innominate artery without
descending aorta) in-plane of nodule was chosen as the
input artery. A region of interest (ROI) with five pixels was
hand drawn in the centre of the descending aorta. Sec-
ondly, three ROIs were hand drawn in every section of the
nodular area of perfusion parametric maps; every ROI was
about 70 pixels; and calcified, cystic, or necrotic areas were
avoided as far as possible. The edges of the nodule were
avoided to prevent partial volume. We examined an ROI
that covered about two-thirds of the diameter of the nod-
ule at the equator if the nodule was smaller.
The time density curves (TDC) of the descending aorta
and pulmonary nodule ROI, peak height (PH), peak
height ratio of pulmonary nodule to aorta (PHpm/PHa),
each type of perfusion parametric maps [blood flow (BF),
blood volume (BV), mean transit time (MTT), permeabil-
ity surface (PS)], and respective perfusion parameters for
all four anatomic section locations available for each
patient were calculated. Representative parameter values
of three groups of pulmonary nodules were then averaged
across the four sections.
Two radiologists experienced in chest CT respectively
observed the TDCs and perfusion parametric maps.
4. Immunohistochemical staining
The position from which the pathologic tissue samples
were drawn as far as possibe kept a parallel with the CT
perfusion section. The tissue in each case was fixed by for-
malin and embedded by paraffin. Paraffin sections (5 μm
thickness) were used for immunohistochemistry using a
streptavidin peroxidase (SP) kit and a hematoxylin and
eosin staining kit. The slices were deparaffinized and
dehydrated in graded alcohols. Heat-induced antigen
retrieval was performed by using a microwave oven and
citrate buffer (pH, 6.0; 10 mol/L). All samples were
immunostained by using the SP procedure with the mon-
oclonal mouse antibodies VEGF (1:100 dilution) and the
monoclonal rabbit antibodies CD34 (1:100 dilution)
(both from Fuzhou Maixin Company, China). The posi-
tive breast cancer paraffin sections supplied with the SP kit
were taken as positive controls and samples with primary
antibody replaced by PBS were taken as negative controls.
VEGF positive brown staining is located in the cytoplasm.
The VEGF staining was graded in terms of its extent and
intensity shown by Mattern et al. [9]. To evaluate the
VEGF expression, a score corresponding to the sum of
both (a) staining intensity (0 = negative; 1 = weak; 2 =
intermediate; 3 = strong) and (b) percentage of positive
cells (0 = 0% positive cells;1 ≤ 25% positive cells; 2 = 25–
50% positive cells; 3 ≥ 50% positive cells) was established.
The sum of (a) and (b) reached a maximum score of 6. We
observed 10 fields of vision by high time lens (×400) and
calculated the average score: 0–2 is negative, more than 2
is positive, between 3 and 4 is weak positive expression,
between 5 and 6 is strong positive expression.
The degree of angiogenesis was determined by means of
MVD measurement in the defined areas of tissue sections
according to the Weidner method [10]. Each slide was first
scanned at low magnification (×100) to determine five
"hotspot" areas where the number of microvessels was at
a maximum. Calcified or necrotic areas were excluded.
MVD was counted in each of the five hotspot areas on a
slide at high magnification (×200). Any one brown stain-
ing endothelial cell or cell cluster that is obviously differ-
ent from peripheral tissues and connective tissues was
counted as a single vessel, and branch construct with dis-
crete breaks was also counted as a single vessel. Appear-
ance of erythrocyte and lumen of vessel may not be taken
as calculation standard for MVD measurement; lumen of
vessel that is more than eight erythrocytes in diameter and
vessel that has thicker muscular layer were also not taken
as calculation standard for MVD measurement.
A pathologist experienced in lung pathology recorded the
histologic diagnosis of each pulmonary nodule. MVD
measurement and VEGF expression were assessed by
means of immunohistochemistry.
5. Data and statistical analysis
The pulmonary nodules were divided into three groups
(peripheral lung cancer, inflammatory nodule, benign
nodule). HU values of 11 time points (2, 6, 10, 14, 18, 22,
26, 30, 34, 38, 42 s) on each TDC of ROI at four anatomicBMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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section locations available for each group of pulmonary
nodules were recorded. Representative HU values of the
respective time point were then averaged (Table 2). The
TDCs of the three groups of pulmonary nodules were
drawn by Graph software (OriginPro 7.5) (Figure 1).
The BV, BF, MTT, PS, PH, PHpm/PHa value of pulmonary
nodule ROI for all four anatomic section locations availa-
ble for each group of patients were recorded. Representa-
tive parameter values were then averaged. All statistical
results were indicated with mean ± SD.
Chi-square test was used among two or three groups of
number datas. P value was calculated by Exact Method.
One-way ANOVA was used to analyze statistical differ-
ences in two or three groups of measurement data, P value
was calculated by LSD Method for equation of variance or
by Tamhane Method for heterogeneity of variance. P val-
ues less than 0.05 were considered to indicate a statisti-
cally significant difference. Pearson coefficients were used
to represent the relationship between the perfusion value
(BV, BF, MTT, PS, PH, PHpm/PHa) and MVD measure-
ment. All statistical analyses were performed by using a
statistical software (SPSS 13.0 for Windows).
Table 2: HU values showing 11 time-points on the TDC of peripheral lung cancer, inflammatory nodule, and benign nodule
Pathologic type 2 S 6 S 10 S 14 S 18 S 22 S 26 S 30 S 34 S 38 S 42 S
Peripheral  lung  11.46 21.66  29.94  36.05  40.76 48.86 51.77 50.16 45.81 43.55 42.16 
Cancer ±4.41 ±6.71 ±7.99 ±9.54 ±10.64 ±10.75 ±10.21 ±10.50 ±9.67 ±10.02 ±9.54
Inflammatory  18.55  35.60  40.86  43.96  50.60 56.97 63.64 60.57 49.52 43.98 42.02 
Nodule ±6.60 ±7.59 ±7.47 ±8.05 ±8.17 ±6.37 ±6.97 ±8.11 ±7.56 ±8.41 ±8.18
Benign nodule 5.68 9.39  12.14  16.41 17.73 19.08 21.84 20.97 20.28 19.68 18.73 
±5.25 ±8.94 ±8.82 ±7.13 ±5.83 ±9.16 ±13.28 ±12.47 ±10.84 ±11.11 ±10.46
*Data is the mean ± SD.
Time density curve of peripheral lung cancer, inflammatory nodule, and benign nodule Figure 1
Time density curve of peripheral lung cancer, inflammatory nodule, and benign nodule.
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Results
1. Time density curve of peripheral pulmonary nodule
The shape of the TDC of peripheral lung cancer was simi-
lar to that of inflammatory nodule. Both showed a steeper
slope, and had an obviously increased nodular HU value.
However, TDC of peripheral lung cancer changed little
after reaching a peak. It became flat at the peak, and had a
platform. However, TDC of inflammatory nodule
declined immediately after reached peak and did not have
a platform. Moreover, inflammatory nodule showed a
higher peak than that of peripheral lung cancer. TDC of
both was obviously different from that of benign nodule,
in which, the TDC changed little, had no steeper slope,
had a flat trend, and had no obvious increase in nodular
HU value (Figures 1, 2A–6A).
2. Immunohistochemistry
In peripheral lung cancers, positive staining of CD34 were
found in the tissues of small artery, small vein, capillary
and blood vessel endothelium of lung cancer tissues,
which were stained brown. Microvascular distributions
were intense in the surrounding and interstitial sub-
stances of the nodules, and blood vessels were rare in
essence and necrotic areas. Many immature tumor capil-
laries were found in the interstitial substance of the nod-
ules. Many single or cluster endothelial cell clumps
showed no lumina or their lumina were closed (Figures
2G–3G). In peripheral lung cancers, VEGF positive stain-
ing was located in the cytoplasm. The size of the cancer
cell nucleus was bigger and atypia of the nucleus was obvi-
ous (Figures 2H, 3H). VEGF expression was found posi-
tive in 29 patients and negative in 10 patients.
In inflammatory nodules, positive staining of CD34
which displayed more expanded mature blood capillaries
were observed (Figure. 4G). VEGF expression in all the 13
cases with inflammatory nodule were negative (Figure
4H).
In benign nodules, positive staining of CD34 manifested
that a smaller quantity of staining tumor capillaries were
observed (Figures 5G, 6G). For VEGF expression, 3
patients were positive, 9 patients were negative (Figures
5H, 6H).
MVD results of peripheral lung cancer, inflammatory nod-
ule and benign nodule were 29.292 ± 14.391, 33.966 ±
15.548, and 7.959 ± 2.328, respectively. MVD values of
peripheral lung cancer and inflammatory nodule were
very high and not statistically significant (P > .05). How-
ever, both MVD values were statistically significant higher
than that of benign nodule (all P < .05) (Tables 3, 4).
MVD among adenocarcinoma, squamous cell carcinoma,
large and small cell carcinoma were not significantly (all
P > 0.05) (Table 5). In the case of adenocarcinoma, MVD
between poorly and well differentiation and between
poorly and moderately differentiation were statistically
significant (all P < 0.05) (Tables 6, 7).
The peripheral lung cancers with VEGF positive expres-
sion showed significantly higher MVD value than that of
peripheral lung cancers with VEGF negative expression (P
< .05). MVD of benign nodules with VEGF positive and
negative expression were not statistically significant (P >
.05) (Table 8).
For VEGF negative expression, MVD of inflammatory
nodule were significantly higher than that of peripheral
lung cancer (P < .05), MVD of benign nodule were signif-
icantly lower than that of peripheral lung cancer and
inflammatory nodule (P < .05) (Tables 8, 9).
3. Perfusion parameters of pulmonary nodules
PH, PHpm/PHa, BF and BV values of peripheral lung can-
cer and inflammatory nodule were not statistically signif-
icant (all P > .05). Both showed significantly higher PH,
PHpm/PHa, BF, BV value than those of benign nodule (all
P < .05). MTT value was not statistically significant among
the three groups of nodules (all P > .05). Peripheral lung
cancer showed significantly higher PS value than that of
inflammatory nodule and benign nodule (all P < .05). PS
value of inflammatory nodule and benign nodule was not
statistically significant (P > .05) (Tables 3, 4).
BV, BF, PS, MTT, PH, and PHpm/PHa among adenocarci-
noma, squamous cell carcinoma, large and small cell car-
cinoma were not significantly (all P > 0.05) (Table 5). In
the case of adenocarcinoma, BV, BF, PS, PHpm/PHa
between poorly and well differentiation and between
poorly and moderately differentiation were statistically
significant (all P < 0.05) (Tables 6, 7).
The peripheral lung cancers with VEGF positive expres-
sion showed significantly higher PH, PHpm/PHa, BF, BV,
and PS values than those of the peripheral lung cancers
with VEGF negative expression, and than those of benign
nodule with VEGF positive expression (Table 8).
In the case of VEGF negative expression, the PH, and
PHpm/PHa of inflammatory nodule were significantly
higher than those of peripheral lung cancer (all P < .05).
The PS of inflammatory nodule was significantly lower
than that of peripheral lung cancer (P < .05). Both BF, BV,
and MTT were not statistically significant (all P > .05). PH,
PHpm/PHa, BF, and BV of benign nodule were signifi-
cantly lower than those of inflammatory nodule (all P <
.05), rather than PS and MTT (all P > .05). PH, PHpm/
PHa, BV, and PS of benign nodule were significantly lowerBMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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(A-H) Poorly differentiated adenocarcinoma found in the apicoposterior segment of superior lobe of the left lung of a 56 year- old male Figure 2
(A-H) Poorly differentiated adenocarcinoma found in the apicoposterior segment of superior lobe of the left lung of a 56 year-
old male. (A) Time density curve. (B-F) (original image, BF, BV, MTT, PS) typeI parametric maps, PS value is higher (30.883). 
(G) CD34 staining shows many immature tumor microvessels (× 200). (H) VEGF expression is strong positive (× 400).
A                                B                                 C    
D                                 E                                 F  
G                                               H  BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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(A-H) Well differentiated squamous cell carcinoma found in the posterior basal segment of inferior lobe of the right lung of a  61-year-old male Figure 3
(A-H) Well differentiated squamous cell carcinoma found in the posterior basal segment of inferior lobe of the right lung of a 
61-year-old male. (A) Time density curve. (B-F) (original image, BF, BV, MTT, PS) TypeII parametric maps, PS value is higher 
(27.051). (G) CD34 staining shows many immature tumor microvessels (× 200). (H) VEGF expression is strong positive (× 
400).
A                                B                                C      
D                                 E                                 F  
G                                             H  BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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(A-H) Inflammatory nodule found in segmentum basale anterius of inferior lobe of the right lung of a 46-year-old male Figure 4
(A-H) Inflammatory nodule found in segmentum basale anterius of inferior lobe of the right lung of a 46-year-old male. (A) 
Time density curve. (B-F) (original image, BF, BV, MTT, PS) TypeIII parametric maps, PS value was lower (5.63). (G) CD34 
staining shows many expanded mature microvessels (× 200). (H) VEGF expression is negative (× 400).
A                                   B                               C      
 D                                 E                                  F  
G                                             H  BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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(A-H) Tuberculoma found in apical segment of superior lobe of the right lung of a 39-year-old female Figure 5
(A-H) Tuberculoma found in apical segment of superior lobe of the right lung of a 39-year-old female. (A) Time density curve. 
(B-F) (original image, BF, BV, MTT, PS) typeI parametric maps, PS value was lower (6.81). (G) CD34 staining shows a few of 
more mature microvessels (× 200). (H) VEGF expression is negative (× 400).
A                                  B                                C     
D                                E                                  F  
G                                               H  BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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(A-H) Hamartoma found in apicoposterior segment of superior of the left lung of a 54-year-old male Figure 6
(A-H) Hamartoma found in apicoposterior segment of superior of the left lung of a 54-year-old male. (A) Time density curve. 
(B-F) (original image, BF, BV, MTT, PS) type I parametric maps, PS value was moderate (12.029). (G) CD34 staining shows a 
few of more mature microvessels (× 200). (H) VEGF expression is negative (× 400).
A                                  B                               C    
D                                 E                                F  
G                                             H  BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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than those of peripheral lung cancer (all P < .05), rather
than BF, and MTT (all P > .05) (Tables 8, 9).
MVD, but not MTT, was positively correlated with PH,
PHpm/PHa, BF, BV, and PS of the peripheral lung cancer
with VEGF positive expression. MVD was positively corre-
lated with PS of the benign nodule with VEGF positive
expression, rather than PH, PHpm/PHa, BF, BV, and MTT.
MVD was not correlated with PH, PHpm/PHa, BF, BV, PS,
as well as MTT of the three groups of pulmonary nodules
with VEGF negative expression (Table 10).
4. Perfusion parametric maps of pulmonary nodules
There were 3 types of CT perfusion parametric maps of
pulmonary nodules. Type I was lack of central blood per-
fusion with sufficient peripheral blood perfusion (Figures
2C–2F, 5C–5F, 6C–6F); Type II was heterogeneity blood
perfusion and much less blood perfusion in the area of
necrosis (Figures 3C–3F); Type III was lack of central and
peripheral blood perfusion (Figures 4C–4F).
There were 21 patients in type I cases (13 peripheral lung
cancers, 2 inflammatory nodules, 4 tuberculoms, 2
hamartomas); 33 patients in type II cases (24 peripheral
lung cancers, 9 inflammatory nodules) and 10 patients in
type III cases (2 peripheral lung cancers, 2 inflammatory,
5 tuberculomas, 1 hamartoma). The perfusion pattern of
peripheral lung cancer and inflammatory nodule was not
statistically significant (F = 2.559, P = 0.298). Both and
benign nodule were statistically significant (F = 19.984, P
= 0.000; F = 13.562, P = 0.001) (Table 11).
The size of the tumor in CT perfusion parametric maps
was smaller than that of CT original images and there were
more exudative process found in the nodules (Figures 4B–
4F).
Discussion
A growing tumor needs added blood supply from adja-
cent tissues, because this is essentially required for tumor
growth and metastatic spread. This process may be caused
by the increasing release of angiogenic factors from the
Table 5: Comparison among the perfusion parameters and MVD of adenocarcinoma, squamous cell carcinoma, large and small cell 
carcinoma
Parameter Cases BV BF MTT PS PH PHpm/PHa MVD
Adenocarcinoma 24 10.173 ± 3.624 225.46 ± 83.132 6.673 ± 3.821 17.819 ± 8.214 62.329 ± 8.084 21.159 ± 3.083 27.483 ± 14.85
Squamous cell 
carcinoma
11 10.244 ± 3.528 164.071 ± 101.015 8.876 ± 3.371 22.217 ± 6.414 56.436 ± 8.456 19.048 ± 3.465 30.828 ± 15.559
Large and small 
cell carcinoma
4 13.92 ± 3.925 197.063 ± 86.943 8.413 ± 3.969 24.093 ± 3.389 63.525 ± 6.52 21.62 ± 2.758 35.918 ± 5.683
*BV, BF, PS, MTT, PH, PHpm/PHa, and MVD among adenocarcinoma, squamous cell carcinoma, large and small cell carcinoma were not significantly (all P > 0.05).
Table 4: Comparison among the perfusion parameters and MVD of three groups of pulmonary nodules
Parameter BV 
(p)
BF 
(p)
MTT 
(p)
PS 
(p)
PH 
(p)
PHpm/PHa 
(p)
MVD 
(p)
Peripheral lung cancer (n = 39) and inflammatory nodule(n = 13) 0.106 0.207 0.345 0.000 0.062 0.107 0.726
Peripheral lung cancer (n = 39) and benign nodule(n = 12) 0.000 0.000 0.146 0.000 0.000 0.000 0.000
Inflammatory nodule(n = 13) and benign nodule(n = 12) 0.013 0.003 0.653 0.990 0.000 0.000 0.000
Table 3: Perfusion parameters and MVD of three groups of pulmonary nodules
Parameter Peripheral lung cancer 
(n = 39)
Inflammatory nodule 
(n = 13)
Benign nodule 
(n = 12)
BV 10.577 ± 3.708 8.542 ± 2.581 5.806 ± 1.628
BF 205.232 ± 90.669 160.902 ± 68.412 80.733 ± 16.060
MTT 7.472 ± 3.760 6.397 ± 3.292 5.760 ± 2.884
PS 19.703 ± 7.660 4.019 ± 1.730 3.797 ± 2.186
PH 60.790 ± 8.336 65.700 ± 5.948 27.833 ± 9.072
PHpm/PHa (100%) 20.611 ± 3.243 22.163 ± 2.240 8.893 ± 2.624
MVD 29.292 ± 14.391 33.966 ± 15.548 7.959 ± 2.328
*Data is the mean ± SD.BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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tumor, such as vascular endothelial growth factor (VEGF),
and subsequent increase in the extent of microvessel den-
sity (MVD) [11-14]. The resulting increase of MVD leads
to increased perfusion and permeability of the blood cap-
illaries. Owing to the increased MVD which is associated
frequently with increased parameter values of a tumor at
CT perfusion imaging [15], CT perfusion imaging can be
interpreted as reflecting tumor vascularity. This discovery
may aid in comparing the differentiation of benignancy
and malignancy of the tumor [16,17].
1. Application value of TDC in the differentiation of 
benignancy and malignancy of the tumor
We want to look into early changes in the TDC in a region
of interest which correlates with blood flow per unit of tis-
sue. It is found that sufficient vascular characterization
may be completely provided in the first scans after an
intravenous bolus of contrast medium. CT perfusion
imaging should be carried out during an early and first-
pass process of contrast medium enhancement. Therefore,
the data acquisition time for scanning is crucial. This
study indicated that more intact TDC of all the nodules
appeared within 40 seconds, and 2-second duration time
after an intravenous bolus of contrast medium was carried
out.
The different appearances of TDC of pulmonary nodules
mainly represented the differences in blood perfusion and
diffusion [18]. This study indicated that TDC of periph-
eral lung cancer had a steeper slope, and there was an
obvious increase of nodular HU value. This changed little
after reaching peak. In fact, it became flat at the peak, and
had a platform. The enhancement of peripheral lung can-
cer and aorta enhanced at an equal pace. However, the
peak of TDC appeared slightly later than that of the aorta.
This was in accordance to the reports of Littleton [19] and
Han Mingjun [20] who proposed that most lung cancers
had abundant vascular supply, which was from the bron-
chial arterial system. The blood perfusion of peripheral
lung cancer is abundant, so, there was a steeper slope in
TDC.
The interstitial space of peripheral lung cancer was found
to be larger, and a near absence or substantial reduction of
lymphatic flow was noted. The retarded flow found in
intravascular and interstitial spaces in the washout phase
from the interstitial space contribute to retention of con-
trast medium in peripheral lung cancer. Thus, TDC of pul-
monary nodule hanged out a little after reaching the peak.
It was found to be flat at peak, with a platform.
This study indicated that TDC of inflammatory nodule
had a steeper slope, which declined immediately after
reaching the peak. It also indicated that in most of the
processes of pulmonary inflammatory nodules, the
number and sizes of bronchial arteries and blood circum-
Table 7: Relationships between adenocarcinoma differentiations and parameters
Parameter BV 
(p)
BF 
(p)
MTT 
(p)
PS 
(p)
PH 
(p)
PHpm/PHa
(p)
MVD
(p)
Well (n = 9) and moderately (n = 10) 0.679 1.000 0.198 0.999 0.738 0.615 0.945
Well (n = 9) and poorly (n = 5) 0.001 0.018 0.897 0.011 0.066 0.038 0.002
Poorly (n = 5) and moderately (n = 10) 0.003 0.025 0.130 0.038 0.035 0.014 0.002
*Because there are fewer cases of squamous cell carcinoma, large and small cell carcinoma, relationships between their differentiations and 
parameters were not compared. In the case of adenocarcinoma, BV, BF, PS, PHpm/PHa, and MVD between poorly and well differentiation and 
between poorly and moderately differentiation were statistically significant (all P < 0.05).
Table 6: Tumor differentiations of adenocarcinoma, squamous cell carcinoma, large and small cell carcinoma
Parameter Differentiation Cases BV BF MTT PS PH PHpm/PHa MVD
Adenocarcino 
ma (24 cases)
well 9 8.706 ± 2.441 205.723 ± 77.469 5.422 ± 1.591 15.949 ± 5.736 61.122 ± 6.371 20.718 ± 3.001 22.451 ± 13.536
moderately 10 9.261 ± 3.448 205.193 ± 90.827 8.755 ± 5.0 15.528 ± 9.547 59.95 ± 6.435 20.069 ± 2.478 22.831 ± 12.514
poorly 5 14.636 ± 2.237 301.518 ± 6.290 4.758 ± 1.919 25.766 ± 4.142 69.26 ± 11.132 24.134 ± 2.889 45.846 ± 4.079
Squamous cell 
carcinoma 
(11 cases)
well 6 10.308 ± 2.729 182.63 ± 105.873 8.362 4.083 20.083 ± 7.198 59.717 ± 5.138 20.342 ± 2.17 28.902 ± 16.223
moderately 4 10.393 ± 5.359 157.448 ± 110.379 9.938 ± 2.759 22.993 ± 3.081 52.825 ± 12.095 17.933 ± 4.852 29.693 ± 16.515
poorly 1 9.26 ± 0.0 79.210 ± 0.0 7.710 ± 0.0 31.92 ± 0.0 51.20 ± 0.0 15.75 ± 0.0 46.93 ± 0.0
Large and 
small cell 
carcinoma 
(4 cases)
well 3 13.743 ± 4.787 165.083 ± 72.129 6.67 ± 2.327 23.003 ± 3.179 60.567 ± 3.356 20.46 ± 1.828 34.993 ± 6.582
moderately 0 0 0 0 0 0 0 0
poorly 1 14.45 ± 0.0 293.0 ± 0.0 13.64 ± 0.0 27.36 ± 0.0 72.4 ± 0.0 25.1 ± 0.0 38.69 ± 0.0BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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fluence of bronchial veins had increased. Moreover, dif-
fused thrombosis at the arterioles of the pulmonary
circulation was observed and the microvessel structure
was found to be made up of coarctate capillary network
from the bronchial artery [19]. Moreover, it was found
that the lung has two systems-bronchial artery and pul-
monary artery of blood supply. When inflammatory nod-
ules, ratio of ventilation and blood flow changed, the
pulmonary arteries became narrow or occlusive, and
bronchial artery became expanded. The vascular supply
was actually found to be from the bronchial arteries. Thus,
blood perfusion of the inflammatory nodule is abundant,
and has a steeper slope in TDC. Flow of contrast medium
through the intravascular space occurred through rela-
tively straight vessels with a normal configuration. There
was an accelerated, active lymphatic flow, and diffusion of
contrast medium increased. Thus, TDC of inflammatory
nodule declined earlier than that of peripheral lung cancer
after reaching the peak.
This study indicated that TDC of benign nodule (tubercu-
loma and hamartoma) manifested as a flat trend. There
was no a steeper slope, or an obvious increase in nodular
CT value. Tuberculoma occurred mainly from caseous
material and hamartoma was mainly from cartilage and
fibrous tissues. Therefore, MVD is smaller, and vascular
supply of tuberculoma and hamartoma is not abundant.
There is lesser blood circumfluence in vessels and
extravascular space. This resulted in a faster diffusion in
tuberculoma and hamartoma. Thus, TDC of benign nod-
ule manifested in a flat trend. Tthere was no steeper slope,
or increase in nodular CT value.
This study indicated that TDC may depict a hemadynamic
character of the pulmonary nodules. These characteriza-
tions may act as reference indexes for differentiating
benign and malignant pulmonary nodules. TDC of
peripheral lung cancer was similar to that of inflammatory
nodule. Both TDC were shown to be obviously different
from that of benign nodule. This coincided with the study
of Zhang et al. [21]. However, Zhang et al. [21] believed
that after inflammatory nodules reached maximum
enhancement, the TDC declined and then rose again. This
did not coincide with our study for two reasons. Firstly,
contrast medium distributed in the vessels rather than in
extravascular space during data acquisition of 40-seconds.
After an intravenous bolus of conventional iodinated con-
trast material, the TDC reflected sufficient vascular charac-
Table 9: Comparison among the perfusion parameters and MVD between VEGF positive and negative expression of three groups of 
peripheral pulmonary nodules
Parameter BV BF MTT PS PH PHpm/PHa MVD
VEGF positive 
expression
Peripheral lung cancer (n = 29) and benign nodule (n = 3) P 0.031 0.007 0.658 0.000 0.000 0.000 0.010
VEGF negative 
expression
Peripheral lung cancer (n = 10) and inflammatory nod (n = 13) P 0.616 0.968 0.308 0.003 0.000 0.001 0.043
Peripheral lung cancer (n = 10) and benign nodule (n = 9) P 0.033 0.114 0.152 0.002 0.000 0.000 0.007
Inflammatory nodule (n = 13) and benign nodule (n = 9) P 0.008 0.003 0.585 0.818 0.000 0.000 0.000
Table 8: Comparison among the perfusion parameters and MVD between VEGF positive and negative expression of three groups of 
peripheral pulmonary nodules
Pulmonary 
nodule
Parameter BV BF MTT PS PH PHpm/PHa 
(100%)
MVD
Peripheral 
lung cancer
VEGF positive 
expression (n = 29)
11.457 ± 3.593 225.406 ± 83.556 7.326 ± 3.807 21.638 ± 7.050 62.531 ± 8.579 21.285 ± 3.238 32.495 ± 14.541
VEGF negative 
expression (n = 10)
8.025 ± 2.859 146.728 ± 88.744 7.896 ± 3.787 14.090 ± 6.785 55.740 ± 5.132 18.657 ± 2.466 20.002 ± 9.363
F 7.449 6.394 0.167 8.680 5.522 5.455 6.400
P 0.010 0.016 0.685 0.006 0.024 0.025 0.016
Inflammatory 
nodule
VEGF positive 
expression (n = 0)
// / / ///
VEGF negative 
expression (n = 13)
8.542 ± 2.581 160.902 ± 68.412 6.397 ± 3.292 4.019 ± 1.730 65.700 ± 5.948 22.163 ± 2.240 33.966 ± 15.548
Benign 
nodule
VEGF positive 
expression (n = 3)
6.620 ± 2.231 83.070 ± 25.153 6.320 ± 1.890 5.047 ± 2.945 30.733 ± 14.199 9.793 ± 4.177 8.877 ± 3.285
VEGF negative 
expression (n = 9)
5.534 ± 1.439 79.954 ± 13.919 5.573 ± 3.222 3.380 ± 1.903 26.867 ± 7.652 8.592 ± 2.168 7.653 ± 2.081
F 1.000 0.078 0.139 1.350 0.386 0.448 0.599
P 0.341 0.786 0.717 0.272 0.548 0.519 0.457
*Data is the mean ± SD.BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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terization but did not reflect TDC of extravascular
characterization in this study. Secondly, this discovery
correlated with the scanner mode and application of the
16-slice spiral CT machine in this study.
TDC of benign nodule was obviously different from that
of peripheral lung cancer and inflammatory nodule.
When TDC manifested as a flat trend, there is neither a
steeper slope nor obvious increase of nodular HU value.
Therefore, morphologic characteristics and patient history
may be used, and tuberculoma or hamartoma may be
considered first before other pulmonary lesions are
proved.
2. Clinical application value of perfusion parameters in the 
differentiation of benignancy and malignancy of tumor
This study indicated that PH, PHpm/PHa, BF, BV value of
peripheral lung cancer and inflammatory nodule were not
statistically significant. Both showed significantly higher
PH, PHpm/PHa, BF, BV value than those of benign nod-
ule. Peripheral lung cancer showed significantly higher PS
value than that of inflammatory nodule and benign nod-
ule. PS value of inflammatory nodule and benign nodule
were not statistically significant. MTT value was not statis-
tically significant among the three groups of nodules. In
the case of adenocarcinoma, BV, BF, PS, PHpm/PHa
between poorly and well differentiation and between
poorly and moderately differentiation were statistically
significant.
The reason may be owing to the fact that the vascular sup-
ply of malignant nodule and inflammatory nodule is
more abundant, and therefore, both blood perfusion have
increased. The vascular supply of benign nodule is lesser,
therefore, its blood perfusion is obviously less than that of
malignant nodule and inflammatory nodule. This coin-
cided with the study results of Swensen et al. [5,7,22,23]
and Zhang et al. [21], who compared PH, PHpm/PHa or
perfusion value of malignant, inflammatory, and benign
nodule, and suggested that malignant and inflammatory
nodule showed higher PH, PHpm/PHa or higher per-
fusion value than those of benign nodule.
Table 11: Type of perfusion parametric maps showing three 
groups of pulmonary nodules
TypeI TypeII Type III
Peripheral lung cancer(n = 39) 13 24 2
Inflammatory nodule(n = 13) 2 9 2
Benign nodule(n = 12) 6 0 6
*The perfusion patterns of peripheral lung cancer and inflammatory 
nodule were not statistically significant (F = 2.559, p = 0.298), but 
both and benign nodule were statistically significant (F = 19.984, P = 
0.000; F = 13.562, P = 0.001).
Table 10: Correlation between MVD and perfusion parameters of three groups of peripheral pulmonary nodules with VEGF positive 
and negative expression
Pulmonary nodule Parameter VEGF positive expression VEGF negative expression
rprp
Peripheral lung cancer BV 0.429 0.020 0.106 0.771
BF 0.432 0.019 0.013 0.971
MTT -0.218 0.256 -0.174 0.630
PS 0.512 0.004 0.114 0.754
PH 0.444 0.016 0.533 0.112
PHpm/PHa 0.415 0.025 0.452 0.190
Inflammatory nodule BV / / 0.135 0.661
BF / / 0.104 0.734
MTT / / -0.252 0.407
PS / / 0.299 0.321
PH / / 0.067 0.829
PHpm/PHa / / 0.344 0.250
Benign nodule BV 0.957 0.188 0.407 0.277
BF 0.996 0.055 0.360 0.341
MTT -0.992 0.083 -0.544 0.130
PS 0.999 0.026 0.535 0.138
PH 0.991 0.086 0.441 0.235
PHpm/PHa 0.983 0.116 0.468 0.203BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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The result of this study indicated that there was a better
consistency among BF, BV, PS, PH, PHpm/PHa in periph-
eral lung cancer, inflammatory nodule, and benign nod-
ule cases. This result suggested that the five perfusion
parameters may better reflect blood perfusion status,
malignant and benign degree of pulmonary nodules.
PS value reflects one-way transmission speed for contrast
material to enter cell spaces by capillary endothelium, and
it reflects the diffusion coefficient of blood vessel
endothelial interspace of tumor angiogenesis. There were
straighter branches of blood vessels, mature blood capil-
laries, and near normal permeability surfaces of blood
capillaries in benign and inflammatory nodules. There-
fore, PS value of inflammatory nodule and benign nodule
was lower, and not statistically significant. For peripheral
lung cancer, there is found to have more developmental
immaturity of tumor capillary, no intact vessel wall, and
increased permeability surface of blood capillary which
resulted from VEGF and other vascular growth factors.
Therefore, the PS value of peripheral lung cancer is higher.
PH, PHpm/PHa, BF, BV value of peripheral lung cancer
and inflammatory nodule were usually significantly
higher than those of benign nodule. Peripheral lung can-
cer usually showed significantly higher PS value than that
of inflammatory nodule and benign nodule. when a pul-
monary nodule shows that PH, PHpm/PHa, BV and BF
are higher, PS is usually higher. It is possible that before
other pulmonary nodules are found, peripheral lung can-
cer may be considered first. When pulmonary nodules
show PH, PHpm/PHa, BV, BF are higher, PS is found to be
lower, and inflammatory nodule may be considered first.
3. Application value of perfusion parametric maps of 
pulmonary nodules
The findings of our study indicated that perfusion map in
type I usually showed up in tuberculoma and hamartoma,
and there was shown to be a lack of central blood per-
fusion, and sufficient peripheral blood perfusion. Per-
fusion map in type II usually showed up in inflammatory
nodule and peripheral lung cancer. In this case, there was
the presence of heterogeneity blood perfusion, and area of
necrosis was found to be less. Perfusion map in type III
usually also showed up in tuberculoma, hamartoma and
inflammatory nodule, and there was found to be a lack of
central and peripheral blood perfusion.
In perfusion parametric map of pulmonary nodule, there
is found to be a lack of central blood perfusion and suffi-
cient peripheral blood perfusion before other pulmonary
lesions are proved. Morphologic characteristics and
patient history may be used, and benign pulmonary nod-
ule (tuberculoma or hamartoma) may be considered first.
However, other pulmonary nodules may found not to
completely excluded, because some adenocarcinomas
may be filled with mucus. Also fewer inflammatory nod-
ules may be filled with pus, and have lack of central per-
fusion.
This study indicated that the low-perfusion area of necro-
sis and mucus or cavitation area could diminish the mean
perfusion parameter values. Therefore, when drawing up
region of interest, it is considered that pulmonary nodule,
low perfusion and cavitation should be avoided as far as
possible.
The size of tumor in CT perfusion parametric maps was
usually smaller than that of original images when there
were more exudative process shown in tumors. Therefore,
CT perfusion parametric maps displayed by color gray
scale may reveal the essence of pulmonary nodules and
differences in regional blood perfusion status more
directly, clearly, realistically, and reliably. This will proba-
bly aid in paracentesis and biopsy of the essence of pul-
monary nodule by CT guidance.
4. Relationship between perfusion parameters and MVD 
and VEGF in pulmonary nodules
Angiogenesis is a complicated process, as it is controlled
by vascular growth factors and vascular growth inhibitor
factors [24,25], This is because the endothelial cells which
have resided in blood capillary and postcapillary vein will
enter again itto cell generation cycle. As a result, there will
be degrading basal membrane under endothelia cells and
this will form blood capillary spore. In turn, blood capil-
lary will move towards peripheral tissues by a pullulate
way. Thus, when a tumor has no passage to directly con-
tact with the eutaxia circulation system, it must induce the
vicinity vessels to erupt the new vessels.
Growth of tumor will suffer limitation if there is occur-
rence of no angiogenesis. Tumor cells obtain nutrition
only when there is diffusion. Tumor will stop growing
after achieving 1–2 nm diameter or thickness of about 107
cells if there is not enough oxygen and nutrition supply.
However, growth of tumor will accelerate once new ves-
sels are put into tumor tissues, and the nutrition supply of
tumor transforms perfusion from diffusion process.
Therefore, the tumor is a growth that typically depends on
supply from the blood vessels. Although there are many
kinds of vascular growth factors, VEGF played a crucial
role in tumor angiogenesis because of its speciality factor
in promoting tumor karyokinesis [25]. MVD is the
number of microvessel per unit area which is counted by
using some specific antibodies (for instance CD34 mono-
clonal antibody)to mark microvessel endothelial cells of
tumor tissues.BMC Cancer 2008, 8:186 http://www.biomedcentral.com/1471-2407/8/186
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This study indicated that in the case of VEGF positive
expression, MVD was found to be positively correlated
with PH, PHpm/PHa, BF, BV, and PS of peripheral lung
cancer. This coincided with the studies of Yi et al. [26],
Tateishi et al. [27] and Li Shenjiang et al. [8]. Yi et al. and
Tateishi et al. described that a significantly positive corre-
lation was found between enhancement of MVD and/or
VEGF of malignant pulmonary nodule. Li Shenjiang et al
[8]. reported that enhancement and perfusion value were
significantly and positively correlated with MVD and
VEGF of malignant pulmonary nodule, and MTT value
was not significantly correlated with MVD and VEGF.
This study also indicated that VEGF expression of 32 cases
(29 peripheral lung cancer, 0 inflammatory nodule, 3
benign nodule) were positive. MVD was not correlated
with PH, PHpm/PHa, BF, BV, and PS of three groups of
pulmonary nodules with VEGF negative expression. The
peripheral lung cancers with VEGF positive expression
showed significantly higher PH, PHpm/PHa, BF, BV, and
PS value than those of the peripheral lung cancers with
VEGF negative expression, and those of benign nodule
with VEGF positive expression.
It is clear that PH, PHpm/PHa, BF, BV, and PS value can
reflect MVD measurement and VEGF expression of benign
and malignant pulmonary nodules. This explains that PH,
PHa/PHpm, BF, BV, PS may act as angiogenesis index of
pulmonary nodules, and have potential value of studied
pulmonary nodule angiogenesis.
Conclusion
16-slice spiral CT perfusion imaging closely correlated
with tumor angiogenesis and reflected MVD measure-
ment and VEGF expression. It provided not only a non-
invasive method of quantitative assessment for blood
flow patterns of peripheral pulmonary nodules.
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